Locking of tunneled hemodialysis catheters with gentamicin and heparin  by McIntyre, Christopher W. et al.
Kidney International, Vol. 66 (2004), pp. 801–805
Locking of tunneled hemodialysis catheters with gentamicin
and heparin
CHRISTOPHER W. MCINTYRE, LISA J. HULME, MAARTEN TAAL, and RICHARD J. FLUCK
Department of Renal Medicine, Derby City General Hospital, Derby, United Kingdom
Locking of tunneled hemodialysis catheters with gentamicin
and heparin.
Introduction. Catheter-related infection (CRI) is a major
cause of morbidity and mortality in patients receiving hemodial-
ysis. Antibiotic locking of these catheters has been shown to in-
crease both the success of systemic antibiotic treatment in line
sepsis, and to reduce the incidence of sepsis. We have studied
the use of gentamicin locking of catheters (in combination with
standard heparin rather than previously reported citrate) to re-
duce CRI rates. Furthermore, we have investigated the effects
of this strategy on epoetin requirements and vascular access
function.
Methods. Fifty patients were studied. Patients were random-
ized to catheter-restricted filling with either standard heparin
(5000 IU/mL) alone, or gentamicin and heparin (5 mg/mL).
Epoetin requirements and hemoglobin response were moni-
tored over the study period.
Results. The gentamicin-locked group suffered only one
infective episode (0.3/1000 catheter days) compared to 10
episodes in six patients in the heparin alone group (4/1000
catheter days, P = 0.02). The isolated organisms were equally
split between Staphylococcal species and coliforms. There were
no statistically significant differences in delivered dialysis dose
(Kt/V) or QA between the two groups. Use of antibiotic lock-
ing was associated with both a higher mean hemoglobin (10.1 ±
0.14 g/dL vs. 9.2 ± 0.17 g/dL in the heparin group, P = 0.003) and
a lower mean epoetin dose (9000 ± 734 IU/week vs. 10790 ±
615 IU/week in the heparin group, P = 0.04).
Conclusion. The practice of locking newly inserted tunneled
central venous catheters with gentamicin and heparin is an ef-
fective strategy to reduce line sepsis rates, and is associated with
beneficial effects on epoetin requirements.
Because of the failure to have formed definitive access
before commencing hemodialysis, or subsequent failure
of established vascular access tunneled and cuffed, cen-
tral venous catheters are being increasingly relied upon
for the provision of vascular access. This is either until
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adequate permanent provision can be made [1], or per-
manently in selected groups of patients [2].
The prevention and management of bacteremia re-
mains a significant clinical challenge in the management
of this form of vascular access. The rates of catheter-
related infection (CRI) associated with this sort of
catheter have been reported to be between 0.2 [3] and
3.9 episodes [4] per 1000 catheter days. The organisms
responsible have been reported, in one representative
study, to be predominantly gram-positive (52.5%), gram-
negative rods (26.7%), and polymicrobial in a further
20.9% [5]. When bacteremia does result, adequate treat-
ment with systemic antibiotics alone is seen in only 25% to
32% of patients [4]. The use of central venous catheters is
also associated with a reduction in responsiveness to epo-
etin, presumably as a consequence of an inflammatory
response brought about by both overt CRI and occult
colonization [6].
There have been a number of strategies utilized to re-
duce the incidence of bacteremia when dealing with long-
term central venous catheters. These include the use of
universal precautions, antibiotic impregnated catheters
[7], silver impregnation of the cuff [8], and avoiding the
use of the femoral vein [9].
Interest has also focused on the use of antimicrobial
locking of the catheters in between each hemodialysis
session. The possible utility of such an approach is re-
inforced by the observation that bacteremia is often as-
sociated with lumenal infection rather than migration of
organisms around the catheter [4]. Concerns have been
raised about stability of the commonly used antibiotics
with heparin, possibly resulting in a concentration in-
sufficient to be active as an antimicrobial, and poten-
tially reducing long-term catheter function and patency
rates (due to precipitation). Gentamicin has been studied
combined with sodium citrate (with its own intrinsic an-
tibacterial action) as an alternative catheter restricted
anticoagulant in an attempt to negate this theoretic prob-
lem [10]. Its use has been shown to reduce line sepsis
rates in a prospective controlled study of new line in-
sertions [11] and increasing clearance rates when com-
bined with systemic antibiotics in the treatment of CRI.
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Gentamicin (at a dose of 5 mg/mL), however, does ap-
pear sufficiently stable when combined with heparin to
maintain a concentration sufficient to decrease the inci-
dence of infection in central venous catheters, with an in
vitro reduction in intralumenal concentration of only 8%
[12]. Heparin is both more familiar and readily available
than citrate in most dialysis units.
The aims of this study were to determine whether a
strategy based on locking with gentamicin and heparin
could reduce the rate of CRI without undesirable effects
on vascular access function. Furthermore, we aimed to
study the impact of such a strategy on anemia and epoetin
requirements.
METHODS
Study design and patients
The investigatory protocol was approved by the Local
Regional Ethics Committee, and all patients gave explicit
written consent. The study was undertaken within a single
hemodialysis (HD) facility based at Derby City General
Hospital. Fifty patients were recruited at the time of inser-
tion of newly tunneled central venous HD catheters over
a one-year period between March 2002 and April 2003.
Patients were randomly allocated to either the standard
catheter restricted solution of heparin (5000 IU/mL in
saline), and antibiotic locking with gentamicin in conjunc-
tion with heparin (gentamicin 5mg/mL, heparin 5000 IU/
mL) before insertion of catheter (replicating concentra-
tion associated with heparin stability). The study was
block randomized with sealed envelopes for patient al-
location, with 25 patients being allocated to each group.
Because of the requirement to make up the gentamicin-
locking solution before instillation (as there was lack of
suitable stability data), it was not possible to blind the
study. Patients were excluded if the catheter was an ex-
change reinsertion, or insertion at a separate site (with
previous catheter still in situ). Patients with recent infec-
tion were excluded, as well as those on immunosuppres-
sant medications. All patients were required to have had
no evidence of CRI, having been antibiotic free for at
least 28 days before catheter insertion. A single catheter
type was used (Kimal KSC split Ash, Kimal, Ltd., Ur-
bridge, England). and was inserted under fluoroscopic
control into either jugular or subclavian veins by an ex-
perienced nephrologist. Femoral devices were excluded
from the study. Patient characteristics in both groups at
initiation of study are summarized in Table 1.
CRI was treated with an empirical regimen based on
vancomycin and gentamicin. This was modified at day
three in light of blood culture data. Catheters were only
exchanged (or removed) if sepsis persisted despite the ini-
tiation of antibiotic therapy. This was defined as failure
to render the patient apyrexial within 48 hours of initiat-
ing therapy. Patients were allowed to remain in the study
after an episode of CRI. However, further CRI episodes
Table 1. Patient characteristics in the two study groups at inclusion
Gentamicin/heparin Heparin
locked locked P value
Age years 63.6 ± 2.8 57.8 ± 3.2 0.22
(26–80) (20–79)
Sex M:F 18:7 14:11 0.45
Diabetic patients % 29% 23% 0.41
Serum ferritin lg/L 245 ± 32.2 298 ± 36.4 0.36
Hemoglobin g/dL 9.64 ± 0.31 9.56 ± 0.28 0.19
Epoetin dose IU/wk 9756 ± 521 9540 ± 471 0.38
were only classified as new infections if they occurred at
least two weeks after cessation of initial successful antibi-
otic therapy.
All patients remained with their originally assigned
locking solution throughout the study unless the patient
was removed from the study due to catheter removal
(failure or removal due to an adequate arteriovenous fis-
tula being available for use). Exit sites were dressed with
oxygen permeable dressings (Opsite, Smith and Nephew,
Hull, England). Additional antimicrobials such as topical
muciprocin were not used. Each exit site was kept under
surveillance by nursing staff at each HD treatment ses-
sion. There were no changes in any practices relating to
dressings or handling of bloodlines over the study period.
Variable infusion rate of heparin was used for anticoag-
ulation, individualized to patient requirements. Catheter
malfunction was defined as a consistent failure to provide
a blood flow >200 mL/min.
Catheter function was followed-up using central au-
tomatic downloading HD-related data from dialysis
monitors to a central server into patient specific files.
Treatments were monitored for blood flow rate and deliv-
ered Kt/V using on-line measurement of Kt/V (Diascan,
Hospal Dasco, Emilia Romagna, Italy). This was further
supplemented by monthly measurement of Kt/V based
on blood urea reduction. Access function was followed
by line failure, urokinase use, and the measurement of
QA utilizing a nonoperator-dependent technique based
on dual measurement of ionic dialysance and flow rever-
sal (using specific crossed line extensions and clamps to
avoid the need to disconnect blood lines) (Hospal Dasco)
[13]. Random predialysis gentamicin levels were taken to
ensure that there was no evidence of systemic exposure
to long-term aminoglycoside. All patients had gentamicin
levels checked at least twice over the study period. Blood
was sampled from the catheter immediately before con-
nection to dialysis line. Formal hearing tests were not per-
formed, but the patients were subjected to direct clinical
inquiry by staff administering the study of any evidence
of aminoglycoside ototoxicity. Patients’ hemoglobin and
epoetin requirements were monitored over the study pe-
riod (Eprex, Ortho Biotec administered iv on HD).
When CRI was clinically suspected cultures were taken
from both peripheral blood and catheter. If the catheter
needed to be removed, both the tip and cuff were sent
to microbiology for culture. CRI was diagnosed using the
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criteria as defined by the Centers for Disease Control
(CDC). This required at least one of the following: (1)
clinical exit site infection with evidence of inflammation
within 2 cm of the exit site; (2) definite bloodstream in-
fection, with isolation of a plausibly significant organism
from catheter and peripheral blood, with no other appar-
ent source of infection; (3) probable bloodstream infec-
tion with defervescence after catheter removal in patients
where both blood and catheter tip infection is not con-
firmed in a symptomatic patient with no other apparent
sources of infection; and (4) possible bloodstream infec-
tion in a symptomatic patient with defervescence after
catheter removal, but who remains culture negative.
Statistical analysis
All analyses were performed on an intention-to-treat
basis. Unpaired data were analyzed using the Mann-
Whitney U test. Cumulative infection-free catheter sur-
vival was assessed by the use of Kaplan-Meier method
and calculated hazard ratio. All data were analyzed using
GraphPad Prism version 3.00 for Windows (GraphPad
Software, San Diego, CA, USA; www.graphpad.com).
Where not otherwise stated, data are expressed as
mean ± SEM (range).
RESULTS
There was no statistically significant difference in mean
number of catheter days per patient in either group
[130.1 ± 16.4 (13–258) and 103 ± 14.6 (14–251) days for
the gentamicin-locked group and heparin-locked groups,
respectively]. Fifty patients were studied; 48% of the
catheters were inserted to start HD in new patients, and
52% were inserted because of existing vascular access
failure pending further surgical intervention. Patients
who had a history of line sepsis with previous catheters in
the previous six months before entry into the study were
equally distributed to both of the study groups (five pa-
tients in the gentamicin-locked arm and four patients in
the heparin alone group).
All episodes of CRI were confirmed on paired culture
of blood from peripheral and line sources from pyrexial
patients. No episodes were associated with exit site infec-
tion alone. There were 10 episodes of CRI in six patients
in the heparin alone treated group. This compared with
a single episode in the gentamicin-locked group. Mean
number of episodes per patient was therefore 0.4 ± 0.16
(0–3) and 0.04 ± 0.04 (0–1) for heparin-locked group
and gentamicin-locked group, respectively (P = 0.03).
If only patients who suffered one episode of CRI are
analyzed, the mean number of CRI episodes is 0.29 ±
0.1 for the heparin-treated group (P = 0.06). Total num-
ber of catheter days accrued in the gentamicin-locked
group was 3252, and 2470 in the heparin alone group. This
equated to a CRI rate of 0.3/1000 catheter days and 4/1000
catheter days for gentamicin-locked group and heparin
Table 2. Summary of data pertaining to CRI during the study period
Gentamicin/heparin Heparin
locked locked P value
CRI total 1 10
Mean number of 0.04 ± 0.04 0.4 ± 0.16 0.03
episodes/patient
CRI rate/1000 0.3 4
catheter days
Time to first CRI days 129.8 ± 16.4 85.3 ± 14.2 0.03
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Fig. 1. Kaplan-Meier cumulative infection-free catheter survival com-
paring gentamicin and heparin (solid line) to heparin alone (dashed
line), P = 0.05.
alone group, respectively. The mean time to first episode
of CRI was also significantly longer in the gentamicin-
treated group [130 ± 16.4 (13–258) days] as compared
with the heparin alone group [85.3 ± 14.2 (14–251) days,
P = 0.03]. This difference remained significantly different
if patients who suffered multiple episodes were excluded
[gentamicin-locked group 130 ± 16.4 (13–258) days] as
compared with the heparin alone group [74 ± 13.1 (14–
244) days, P = 0.02]. In patients who experienced multiple
episodes of CRI during the study, the minimum inter-
val of being sepsis free off antibiotic therapy between
infections was 27 days (CRI data are summarized in
Table 2). On retrospective review, 11 of the 25 patients in
the gentamicin-locked group had had a catheter in place
in the previous six months prior to recruitment into the
study. This was in comparison to only 6 patients in the
heparin only group. There were 10 episodes of CRI in
five of the patients during a total of 1257 catheter days
(rate 7.9/1000 catheter days). There were no documented
exit site infections. During the study the 10 episodes of
CRI had resulted from three Staphylococcus aureus, two
Staphylococcus epidermis, one MRSA, three Escherichia
coli, and one Klebsiella isolate. In the four patients who
experienced two episodes of CRI over the study period,
all of the second episodes of CRI were a different isolated
organism from the first. This indicates that colonization
was not a significant factor in these patients. Infection-
free survival (to first CRI episode only) was significantly
different in the two groups (P = 0.05, hazard ratio 0.16)
(Fig. 1). The single CRI in the gentamicin-locked group
was due to MRSA.
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Fig. 2. Box and whisker plot of hemoglobin over the study period in
the two groups (P = 0.003).
There were no significant differences in catheter func-
tion in either group. Delivered mean Kt/V was 0.98 ±
0.05 (0.4–1.5) and 1.05 ± 0.05 (0.5–1.5), P = 0.24, for
gentamicin-locked and heparin alone groups, respec-
tively. Mean QA over the study period was also not
different in the two groups, 1484 ± 95.6 (954–2141)
mL/min and 1373 ± 94.5 (1054–2091) mL/min, P = 0.62,
for gentamicin-locked group and heparin, respectively.
There was no difference in the amount of urokinase in-
fusions or locks required to maintain patency in either
group. Only two catheters in the heparin group, and one
in the gentamicin-locked group, were removed due to ac-
cess failure. No catheters were removed due to failure of
initial antibiotic therapy to treat CRI.
Mean hemoglobin (mean derived from measurements
taken over the entire study period) was lower in the
heparin-treated group at 9.24 ± 0.17 (5.6–12.6) g/dL com-
pared with a mean hemoglobin of 10.05 ± 0.14 (6.2–13.6)
g/dL in the gentamicin-locked group (P = 0.003) (Fig. 2).
This was despite the mean epoetin dose (mean derived
from measurements taken over the entire study period)
being higher at 10,790 ± 615 (3000–20,000) IU/week in
the heparin group compared to 9000 ± 735 (2000–20,000)
IU/week in the gentamicin-locked group (P = 0.04)
(Fig. 3). These were still significantly different when ad-
justed for body weight, 163.2 ± 11.4 IU/kg/week in the
heparin group compared to 126.7 ± 10.2 IU/kg/week in
the gentamicin-locked group (P = 0.03). Any patients
who received a transfusion were excluded from this sec-
tion of the analysis (only two patients in each group
received blood transfusion). When patients who had ex-
perienced CRI were excluded the trend toward higher
hemoglobin concentration (mean Hb 9.8 ± 0.3 vs. 9.23 ±
0.04 in the heparin alone–treated group) and lower epo-
etin requirements (8780 ± 458 U/week vs. 9560 ± 632
U/week in the heparin-treated group) in the gentamicin
group persisted but did not reach statistical significance
(P = 0.06). There was no difference in the mean ferritin
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Fig. 3. Box and whisker plot of epoetin dose over the study period in
the two groups (P = 0.04).
(298 ± 35.1 and 312 ± 32.7 lg/L for gentamicin-locked
and heparin patients, respectively, P = 0.34), parathy-
roid hormone (PTH) (214 ± 22.8 and 256 ± 31.5 nmol/L
for gentamicin-locked and heparin patients, respectively,
P = 0.25), or Kt/V between the two groups over the study
period. There was a similar use of statins in the two groups
(32% and 25% in the heparin alone and gentamicin-
locked groups, respectively).
All random gentamicin levels were <0.2 mg/L, and
no patients complained of any symptoms that might
be attributable to aminoglycoside toxicity. No gentam-
icin/heparin solutions were discarded due to obvious tur-
bidity after constitution. The total gentamicin costs per
year/patient were around £100.
DISCUSSION
This is the first study to demonstrate that a low-cost
strategy of combining gentamicin with heparin for the
catheter-restricted filling of HD catheters is capable of
reducing CRI incidence. Furthermore, such a strategy
is also associated with improved hemoglobin concentra-
tions and reduced epoetin requirements.
The incidence of CRI in the control group was in keep-
ing both with unit specific historical data and published
studies [11, 14]. The reduction in CRI rate was almost
identical to that reported for the combination of gentam-
icin and bacteriocidal/anticoagulant citrate [11]. There
was almost complete abolition of CRI in the gentamicin-
treated group. This would support in vitro data [12]
that gentamicin does remain biologically active, without
significant precipitation when combined with heparin.
Citrate is less desirable to use instead of heparin due to
the increased treatment costs, increased difficulty in en-
suring adequate and reliable anticoagulation of the ex-
tracorporeal circuit, and the possibility (at higher doses)
of chelation of calcium. The issues of systemic exposure
obviously are not an issue if the use of citrate is restricted
to catheter volume alone. The use of high concentration
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gentamicin allows it to be bacteriocidal to a wide range
of likely causative organisms (gram-positive and gram-
negative). The causative organisms were also similar in
distribution to the study by Dogra et al (despite mu-
ciprocin not being in use). The bacteriologic profile was
also similar to those identified historically within our
unit. The possibility of this approach encouraging the de-
velopment of gentamicin-resistant organisms cannot be
excluded from these data. However, the high concentra-
tion of gentamicin used and apparent lack of systemic
exposure make this less likely. The risk needs also to
be offset by the propensity of multiple exposures to an-
tibiotics for the treatment of CRI, which this strategy
markedly reduces.
Unlike the previous study of gentamicin locking, we
found no adverse effects attributable to gentamicin toxi-
city. There was no measurable systemic exposure to gen-
tamicin in any of the patients studied. This would imply no
splannation or excessive locking of the catheters. How-
ever, the gentamicin levels were reported as <0.2 mg/L,
and the authors cannot exclude the possibility of long-
term exposure to such low levels of aminoglycoside. Al-
though this did not appear to be associated with any clini-
cal adverse effects, hearing was not formally tested, and it
would be wise to review this practice in the light of long-
term safety data. In the study by Dogra et al there was a
trend to worse catheter functioning in the heparin alone–
treated group. This was studied using relatively crude
measures of catheter loss. We were unable to demonstrate
any difference between the two groups when considering
delivered Kt/V, urokinase usage, catheter loss, or actual
measurement of QA. These data would suggest that gen-
tamicin deposition did not occur to any hemodynamically
appreciable degree within the catheters. All solutions of
gentamicin and heparin were made up by the bedside
(without any visual turbidity). Further formal studies of
longer term stability are required to assess how far in
ahead solution could be preprepared to simplify the de-
livery of the HD treatment for dialysis nurses.
This study demonstrated an association between the
locking of catheters with gentamicin and improved
hemoglobin concentrations with reduced epoetin re-
quirements. This may be as a result of the reduction in
recognized CRI, or there might be an effect of reduction
in covert bacterial colonization. This study only demon-
strates an association of gentamicin locking of catheters
with higher hemoglobin concentrations and lower epo-
etin doses. The use of iron therapy and PTH were not sta-
tistically significantly different between the two groups,
but the study did not have sufficient patients within it to
establish an effect of differences in the factors known to
influence epoetin responsiveness in the patients who had
experienced CRI. Likewise, there was difference in statin
usage given the potential impact of this on epoetin re-
sponsiveness [15]. There were no differences in the level
of small solute removal in the two groups. This makes
differences in epoetin response between the two groups
unlikely to be due to dialysis issues [16, 17].
CONCLUSION
The practice of catheter-restricted filling of tunneled
HD catheters with gentamicin and heparin markedly re-
duces the incidence of CRI, with no obvious adverse con-
sequences in terms of aminoglycoside exposure or vascu-
lar access function. This strategy appears to have further
beneficial implications on treatment costs due to a reduc-
tion in epoetin requirements.
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